Search

Congress platform

The EHA2024 Hybrid Congress content is entirely accessible on the Congress platform.  

Access the EHA2024 Congress platform 

To access the Congress platform, please use your credentials.

Read more

A well-attended second meeting from the European Hematology Association (EHA) and the EHA Scientific Working Group on Red Cell and Iron

For the second time the European Hematology Association (EHA) and the EHA Scientific Working Group on Red Cell and Iron joined in the organization of the meeting focused on Red Cell and Iron Metabolism Defects: From basic science to clinical…

Read more

Expert opinions for specific non-malignant hematologic diseases

Red Cells and Iron
Hemoglobinopathies: Sickle Cell Disease and Thalassemia

Sickle Cell Disease Association of America (SCDSS)
Sickle Cell Disease and COVID-19: An Outline to Decrease Burden and Minimize Morbidity 
Italian Society of Thalassemia and Hemoglobinopathies

Thalassemia and Hemoglobin disorders Italian Society
Thalassemia International Federation (TIF)
The COVID-19…

Read more

Abstract submission & Awards

Abstract and Case Report submission is now closed. Abstract awardsIntroduced in 2021 and after 3 editions, we are excited to announce the 4th Emerging Investigators EHA-EBMT Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy 2024.

Read more

Open Access: the ‘Plan S’

 

Research and academic groundwork funded with public means should be free and open to everyone. That is the principle behind Open Access that was formulated in 2003 in the Berlin Declaration.

Read more

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more